Development in ICT and strategic opportunities offered for competitive Essay

Development in ICT and strategic opportunities offered for competitive advantage in organisations - Essay Example Founded in 1984 by Leonard Bosack and sandy Lemer, a husband and wife team of academics from Stanford University, as a means of sending data between computers. Cisco has grown to be the company that, according to David Stauffer in Business the Cisco Way, is the company that makes the Internet. Cisco's networking products are designed to connect people, computing devices and computer networks, allowing access or information transfer regardless of differences in time, place or type of computer system. Cisco provides end-to-end networking solutions that customers use to build their own unified information infrastructure or to connect to and outside network. And end-to-end networking solution is defined as one that provides a common architecture that delivers consistent network services to all users. The broader the range of network services, the more capabilities a network can provide to users connected to it and thus the more effective it is. Large organisations with complex networking needs, spanning multiple locations and with many types of computer systems. Such customers include major corporations, government agencies, pan-governmental organisations, public utilities and educational institutions. Cisco operates in over 115 countries using a direct sales force, distributors, value-added resellers and system integrators. The company is headquartered in San Jose, CA. With major operations in Research Triangle Park, NC, and Chelmsford, MA; as well more than 225 sales and support offices in 75 countries. As a company that is in tune with the individual needs of its customers Cisco does not take a rigid, product-led approach that favours one particular solution regardless of the fit with customer requirements. Cisco's philosophy is to listen to customer needs and then develop solutions for discussion to ensure that those needs are met- a customer driven approach. Cisco's strategy: This high-tech company has the strategy of being a one-stop shopping provider of networking equipment. Operating models include a well-honed model for acquiring

Initial Public Offering of Amphastar Pharmaceuticals Assignment - 2

Initial Public Offering of Amphastar Pharmaceuticals - Assignment Example This research will begin with the statement that the business of Amphastar Pharmaceuticals is the development, production and the marketing of both generic and proprietary inhalable and injectable chemicals in the USA. Currently, the company is selling fifteen products, while at the same time in the process of developing thirteen more proprietaries as well as seven generic product portfolios, which will feature in the market in the near future. Â  The company prides more in its high technical and technological capability that is the main business strength that enables the company overcome competition in its field, through the introduction of innovative technologies such as the production of a variety of pre-filled syringes, and metered-dose inhalation technology. The terms of the Initial Public Offering of the Amphastar Pharmaceuticals shares is through the use of prospectus, which acts as the registration statement for the shares, and the copies of the prospectus were being offered by the underwriters of the company shares, Jefferies LLC, from their offices. Thus, the press statements and advertisements of the IPO did not constitute an offer for sale, until the prospective buyer of the shares had obtained the copy of the prospectus and filled it. Therefore, the shares had been divided into various categories, comprising of 4,640,000 common stock shares that were directly offered by Amphastar Pharmaceuticals and common stock 3,360,000 shares that were being offered by the company’s stockholders. Additionally, the underwriters of the company, Jefferies LLC, are reserved 1,200,000 additional shares which were available for over-allotment, offered as an option for the prospective buyers to buy more shares. The company is offered 5,800,000 shares at an initial price of $7 per share, which constituted $40,900,000, but the Pharmaceutical Company paid a total of $6,200,000 in brokerage commissions and underwriting discounts, thus remaining with a total of $34, 700,000. The percentage of the commission to the broker-dealers, as well as the underwriter's discounts and other IPO issuing expenses, amounted to $6,200,000 of the total 40,900,000, which is approximately 15.2%.